Replies to post #5248 on Biotech Values

[DewDiligence]

Re: ORPH

>> I think it's an unlikely scenario that someone comes in and develops GHB for a new indication to work around xyrems orphan status. We're talking about a $10M selling drug with optimistic upside of $100M or so (imo). I don't think the return would be there for a second entrant. <<

Fair enough. Have you bought any yet?